Protein arginine methyltransferases (PRMTs) have been implicated in the progression of many diseases. Understanding substrate recognition and specificity of individual PRMT would facilitate the discovery of selective inhibitors towards future drug discovery. Herein, we reported the design and synthesis of bisubstrate analogues for PRMTs that incorporate a S-adenosylmethionine (SAM) analogue moiety and a tripeptide through an alkyl substituted guanidino group. Compound AH237 is a potent and selective inhibitor for PRMT4 and PRMT5 with a half-maximal inhibition concentration (IC50) of 2.8 and 0.42 nmol/L, respectively. Computational studies provided a plausible explanation for the high potency and selectivity of AH237 for PRMT4/5 over other 40 methyltransferases. This proof-of-principle study outlines an applicable strategy to develop potent and selective bisubstrate inhibitors for PRMTs, providing valuable probes for future structural studies.
Keywords: Bisubstrate analogue; Bisubstrate inhibitor; GAR, glycine and arginine; IC50, half-maximal inhibition concentration; NTMTs, N-terminal methyltransferases; PKMTs, protein lysine methyltransferases; PRMTs, protein arginine methyltransferases; Protein arginine methyltransferase; Protein arginine methyltransferase 4; Protein arginine methyltransferase 5; SAH, S-(5′-adenosyl)-l-homocysteine; SAM, S-adenosylmethionine; SNF, sinofungin; TLC, thin-layer chromatography.
© 2021 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.